Literature DB >> 19656915

Omega-3 fatty acid supplementation attenuates oxidative stress, inflammation, and tubulointerstitial fibrosis in the remnant kidney.

Won Suk An1, Hyun Ju Kim, Kyu-Hyang Cho, Nosratola D Vaziri.   

Abstract

Significant reduction of renal mass initiates a series of hemodynamic and nonhemodynamic events which lead to proteinuria, glomerulosclerosis, tubulointerstitial injury, and end-stage renal failure. Lipid mediators derived from fatty acids participate in regulation of renal hemodynamic and nonhemodynamic processes that influence progression of renal disease. Composition of cellular fatty acids and hence related signaling responses are influenced by their dietary contents. Consumption of omega-3 fatty acids (O-3FA) has proven effective in mitigating atherosclerosis. We tested the hypothesis that O-3FA supplementation may retard progression and attenuate upregulation of pathways involved in oxidative stress, inflammation, and fibrosis in rats with renal mass reduction. Sprague-Dawley rats were subjected to 5/6 nephrectomy [chronic renal failure (CRF)] and randomly assigned to the untreated and O-3FA-treated (0.3 g.kg(-1).day(-1) by gastric gavage for 12 wk) groups. Sham-operated rats served as controls. The untreated CRF rats exhibited proteinuria, hypertension, azotemia, upregulations of renal tissue NAD(P)H oxidase, MCP-1, COX-2, PAI-1, TGF-beta, Smad2, alpha-smooth muscle actin, fibronectin, and hepatocyte growth factor, activation of ERK1/2 and NF-kappaB, downregulation of Smad7, intense mononuclear leukocyte infiltration, tubulointerstitial fibrosis, and glomerulosclerosis. O-3FA supplementation significantly lowered COX-2, NAD(P)H oxidase (NOX-4, gp91(phox), p47(phox), p22(phox)), PAI-1, TGF-beta, connective tissue growth factor, alpha-smooth muscle actin, fibronectin, Smad2, and MCP-1, raised Smad7, and attenuated ERK1/2 and NF-kappaB activation, tubulointerstitial fibrosis, and inflammation. Thus, long-term O-3FA supplementation can reduce or reverse upregulation of prooxidant, proinflammatory, and profibrotic pathways and attenuate tubulointerstitial fibrosis in the remnant kidney.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19656915     DOI: 10.1152/ajprenal.00217.2009

Source DB:  PubMed          Journal:  Am J Physiol Renal Physiol        ISSN: 1522-1466


  54 in total

Review 1.  How the kidney is impacted by the perinatal maternal environment to develop hypertension.

Authors:  Ana D Paixão; Barbara T Alexander
Journal:  Biol Reprod       Date:  2013-12-19       Impact factor: 4.285

2.  The interaction between ApoA2 -265T>C polymorphism and dietary fatty acids intake on oxidative stress in patients with type 2 diabetes mellitus.

Authors:  Elham Zamani; Haleh Sadrzadeh-Yeganeh; Gity Sotoudeh; Laleh Keramat; Mohammadreza Eshraghian; Masoumeh Rafiee; Fariba Koohdani
Journal:  Eur J Nutr       Date:  2016-06-06       Impact factor: 5.614

3.  Different administration schedules of darbepoetin alfa affect oxidized and reduced glutathione levels to a similar extent in 5/6 nephrectomized rats.

Authors:  Péter Monostori; Gabriella F Kocsis; Zsuzsanna Ökrös; Péter Bencsik; Orsolya Czétényi; Zoltán Kiss; Balázs Gellén; Csaba Bereczki; Imre Ocsovszki; Judit Pipis; János Pálóczi; Márta Sárközy; Szilvia Török; Ilona S Varga; István Kiss; Eszter Fodor; Tamás Csont; Péter Ferdinandy; Sándor Túri
Journal:  Clin Exp Nephrol       Date:  2012-12-06       Impact factor: 2.801

4.  Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure.

Authors:  Steven T Haller; David J Kennedy; Amjad Shidyak; George V Budny; Deepak Malhotra; Olga V Fedorova; Joseph I Shapiro; Alexei Y Bagrov
Journal:  Am J Hypertens       Date:  2012-03-01       Impact factor: 2.689

Review 5.  Role of triglyceride-rich lipoproteins in diabetic nephropathy.

Authors:  John C Rutledge; Kit F Ng; Hnin H Aung; Dennis W Wilson
Journal:  Nat Rev Nephrol       Date:  2010-05-04       Impact factor: 28.314

6.  Passive immunization against marinobufagenin attenuates renal fibrosis and improves renal function in experimental renal disease.

Authors:  Steven T Haller; Christopher A Drummond; Yanling Yan; Jiang Liu; Jiang Tian; Deepak Malhotra; Joseph I Shapiro
Journal:  Am J Hypertens       Date:  2013-09-06       Impact factor: 2.689

Review 7.  Natural antioxidants in the treatment and prevention of diabetic nephropathy; a potential approach that warrants clinical trials.

Authors:  Noori Al-Waili; Hamza Al-Waili; Thia Al-Waili; Khelod Salom
Journal:  Redox Rep       Date:  2017-03-09       Impact factor: 4.412

8.  Plasma alpha-tochopherol determined by HPLC in dogs at different stages of chronic kidney disease: a retrospective study.

Authors:  Ilaria Lippi; F Perondi; V Meucci; C Mannarini; L Intorre; G Guidi
Journal:  Vet Res Commun       Date:  2017-05-09       Impact factor: 2.459

Review 9.  Lipotoxicity as a trigger factor of renal disease.

Authors:  Adriana Izquierdo-Lahuerta; Cristina Martínez-García; Gema Medina-Gómez
Journal:  J Nephrol       Date:  2016-03-08       Impact factor: 3.902

Review 10.  Remnant nephron physiology and the progression of chronic kidney disease.

Authors:  H William Schnaper
Journal:  Pediatr Nephrol       Date:  2013-05-29       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.